The impact of chronic pain and depression on medication for opioid use disorder treatment: A mixed-methods analysis.

Chronic pain Depression Medication for opioid use disorder Opioid use disorder Treatment engagement Treatment retention

Journal

Heroin addiction and related clinical problems
ISSN: 1592-1638
Titre abrégé: Heroin Addict Relat Clin Probl
Pays: Italy
ID NLM: 101170415

Informations de publication

Date de publication:
2024
Historique:
pmc-release: 01 01 2025
medline: 29 7 2024
pubmed: 29 7 2024
entrez: 29 7 2024
Statut: ppublish

Résumé

Opioid use disorder (OUD) is associated with significant morbidity and mortality. Medication for opioid use disorder (MOUD) is a cost-effective treatment, but retention rates vary widely. Mixed methods studies are needed to better understand how depression and pain impact the experience of OUD and MOUD treatment experiences. Participants were recruited from an urban addiction treatment center in the United States. Along with demographic characteristics, current pain severity, pain interference, pain catastrophizing, and depression were assessed via self-report. Correlational analyses, multivariable logistic regression models, Fisher exact tests, and Wilcoxon signed rank tests were used to examine the impact of demographic characteristics, physical pain, and depression on multiple treatment outcomes: 90-day treatment engagement (total number of dispensed MOUD doses), retention (yes/no still in treatment at 90 days), and opioid use (positive/negative urinalysis for opioids at 90 days). Ten participants were interviewed about their history with physical pain, depression, opioid use, and OUD treatment experiences. Themes were identified using a rapid analysis, top-down approach. Fifty participants enrolled in the study and received buprenorphine (12%) or methadone (88%). Older age was associated with 90-day treatment engagement. Higher depression scores were associated with a positive opioid urinalysis at 90-day follow-up. In interviews, participants reported experiencing chronic physical pain and depression before and during their OUD and an interest in addressing mental and physical health in addiction treatment. Addressing co-occurring physical and mental health concerns during MOUD treatment has the potential to improve the treatment experience and abstinence from opioids.

Sections du résumé

Background UNASSIGNED
Opioid use disorder (OUD) is associated with significant morbidity and mortality. Medication for opioid use disorder (MOUD) is a cost-effective treatment, but retention rates vary widely.
Aim UNASSIGNED
Mixed methods studies are needed to better understand how depression and pain impact the experience of OUD and MOUD treatment experiences.
Methods UNASSIGNED
Participants were recruited from an urban addiction treatment center in the United States. Along with demographic characteristics, current pain severity, pain interference, pain catastrophizing, and depression were assessed via self-report. Correlational analyses, multivariable logistic regression models, Fisher exact tests, and Wilcoxon signed rank tests were used to examine the impact of demographic characteristics, physical pain, and depression on multiple treatment outcomes: 90-day treatment engagement (total number of dispensed MOUD doses), retention (yes/no still in treatment at 90 days), and opioid use (positive/negative urinalysis for opioids at 90 days). Ten participants were interviewed about their history with physical pain, depression, opioid use, and OUD treatment experiences. Themes were identified using a rapid analysis, top-down approach.
Results UNASSIGNED
Fifty participants enrolled in the study and received buprenorphine (12%) or methadone (88%). Older age was associated with 90-day treatment engagement. Higher depression scores were associated with a positive opioid urinalysis at 90-day follow-up. In interviews, participants reported experiencing chronic physical pain and depression before and during their OUD and an interest in addressing mental and physical health in addiction treatment.
Conclusions UNASSIGNED
Addressing co-occurring physical and mental health concerns during MOUD treatment has the potential to improve the treatment experience and abstinence from opioids.

Identifiants

pubmed: 39069987
doi: 10.62401/2531-4122-2024-15
pmc: PMC11271030
pii:
doi:

Types de publication

Journal Article

Langues

eng

Déclaration de conflit d'intérêts

Conflict of interest All authors do not have any financial relationships with commercial interests to report.

Auteurs

Corinne N Kacmarek (CN)

US Department of Veterans Affairs Mental Illness Research Education and Clinical Center, Baltimore, MD, USA.

Hannah C Smith (HC)

University of Maryland School of Medicine, Department of Psychiatry, Division of Addiction Research and Treatment, Baltimore, MD, USA.

Maxwell Kuehn (M)

University of Michigan Medical School, Ann Arbor, MI, USA.

Melanie E Bennett (ME)

University of Maryland School of Medicine, Department of Psychiatry, Division of Addiction Research and Treatment, Baltimore, MD, USA.
US Department of Veterans Affairs Mental Illness Research Education and Clinical Center, Baltimore, MD, USA.

Annabelle Belcher (A)

University of Maryland School of Medicine, Department of Psychiatry, Division of Addiction Research and Treatment, Baltimore, MD, USA.

Heather Fitzsimons (H)

University of Maryland School of Medicine, Department of Psychiatry, Division of Addiction Research and Treatment, Baltimore, MD, USA.

William Hall (W)

Johns Hopkins School of Medicine, Baltimore, MD, USA.

Aaron Greenblatt (A)

University of Maryland School of Medicine, Department of Psychiatry, Division of Addiction Research and Treatment, Baltimore, MD, USA.

Lan Li (L)

University of Maryland School of Medicine, Department of Psychiatry, Division of Addiction Research and Treatment, Baltimore, MD, USA.

Letitia E Travaglini (LE)

US Department of Veterans Affairs Mental Illness Research Education and Clinical Center, Baltimore, MD, USA.

Classifications MeSH